Trials / Completed
CompletedNCT00286780
Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia
A Phase 2, Open Label Study of AT-101 in Combination With Rituximab in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Ascenta Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label Phase 2 study to evaluate the safety and efficay of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AT-101 | 80 mg of AT-101 once daily for three days every other week, 375 mg/m2 of rituximab weekly for up to 12 weeks |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2007-11-01
- Completion
- 2007-11-01
- First posted
- 2006-02-06
- Last updated
- 2010-08-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00286780. Inclusion in this directory is not an endorsement.